Colorectal Cancer Screening: What the Main Options Actually Involve

TLDR

For adults at average risk, colorectal cancer screening generally begins at age 45. Options include at-home stool tests, colonoscopy, CT colonography and flexible sigmoidoscopy. Colonoscopy is the most comprehensive single procedure because it can find and remove polyps, but it requires bowel preparation and usually sedation. Stool tests are easier to complete at home, but they must be repeated on schedule. Any abnormal non-colonoscopy result needs a follow-up colonoscopy—not another screening test—to complete the process.

The best screening test is usually the one a person can complete correctly and repeat at the recommended interval. The choice should also account for medical history, willingness to undergo preparation or sedation, access, insurance coverage and the likelihood of completing follow-up care.

Who should begin screening, and when?

The 2026 American Cancer Society guideline recommends regular screening beginning at age 45 for adults at average risk. The U.S. Preventive Services Task Force recommendation also covers average-risk adults ages 45 through 75, with selective screening from ages 76 through 85. For older adults, health, life expectancy, screening history and personal preferences become increasingly important. The American Cancer Society discourages screening after age 85.

These recommendations concern people without symptoms. Rectal bleeding, persistent changes in bowel habits, unexplained iron-deficiency anemia or other concerning symptoms call for diagnostic evaluation rather than routine screening. A personal or family history of colorectal cancer or certain polyps, inflammatory bowel disease, a hereditary cancer syndrome or previous abdominal or pelvic radiation can also change when and how screening should occur. Recording diagnoses and ages of onset in a useful family health history can help a clinician assess that risk more accurately.

The main colorectal cancer screening options

Option	Usual interval for average-risk screening	What it involves	Important tradeoff
FIT	Every year	One stool sample collected at home; generally no dietary or medication restrictions	Convenient, but must be repeated annually
High-sensitivity gFOBT	Every year	Multiple stool samples collected at home	Dietary or medication restrictions may apply
Multitarget stool DNA or stool RNA test	Every three years under the ACS guideline	At-home stool collection analyzed for molecular markers and blood	Less frequent than FIT, but an abnormal result still requires colonoscopy
Colonoscopy	Every 10 years	Bowel preparation followed by examination of the entire colon, usually with sedation or anesthesia	Can remove polyps during the procedure but is more invasive
CT colonography	Every five years	Bowel preparation followed by a CT-based examination; generally no sedation	Uses radiation and cannot remove a detected polyp
Flexible sigmoidoscopy	Every five years under the ACS guideline	Bowel preparation followed by examination of the rectum and lower colon	Does not examine the entire colon

These intervals reflect options in the 2026 American Cancer Society guideline for average-risk adults. The USPSTF’s 2021 recommendation includes similar established options but also describes stool DNA-FIT every one to three years and flexible sigmoidoscopy every 10 years when combined with annual FIT. A clinician may recommend a different schedule when previous findings or individual risk factors change the situation.

At-home stool tests

Fecal immunochemical testing, or FIT, looks for human hemoglobin in stool. It generally requires one sample and does not require the dietary or medication restrictions associated with high-sensitivity guaiac fecal occult blood testing, or gFOBT. Low-sensitivity gFOBT is not recommended.

Multitarget stool tests combine blood detection with molecular markers. The ACS guideline lists stool DNA and, as of its 2026 update, multitarget stool RNA testing at three-year intervals. Stool-based screening avoids bowel preparation and can be completed at home, but convenience does not eliminate the need for consistency: a test due annually only works as an annual strategy when it is actually repeated.

Colonoscopy

Colonoscopy examines the full colon with a flexible instrument. It can also allow a clinician to biopsy abnormal tissue or remove polyps during the same procedure, making it both a detection and prevention tool. Preparation requires clearing the bowel, and the procedure is commonly performed with sedation or anesthesia. Bleeding and perforation are uncommon but possible, particularly when tissue is removed, and procedural risks increase with age.

For an average-risk person with a normal result, the usual screening interval is 10 years. That long interval is an advantage, but practical issues—preparation, transportation after sedation, time away from work and access to an endoscopy facility—may influence whether it is the most workable first choice.

CT colonography and flexible sigmoidoscopy

CT colonography uses imaging to examine the colon. It still requires bowel preparation, but it generally does not require sedation. It uses radiation and may reveal findings outside the colon that lead to additional evaluation. Flexible sigmoidoscopy uses an instrument to inspect the rectum and lower portion of the colon, rather than the entire organ, and also requires preparation.

Neither test can remove a polyp during the screening exam. If either identifies a concerning finding, colonoscopy is needed for further evaluation and possible removal.

What about a blood test?

The FDA approved the Shield blood test in July 2024 for colorectal cancer screening in average-risk adults age 45 or older. A positive result should be followed by colonoscopy. The FDA states that the test is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in people at higher risk. FDA information about the Shield blood test provides the approved-use details.

The ACS does not currently classify blood-based screening as a preferred option. Its 2026 guideline says blood tests should be offered to people who decline or do not complete preferred stool-based or structural options, citing lower sensitivity for advanced precancerous lesions and stage I cancers. In practical terms, a blood test may be preferable to no screening, but it should not automatically be treated as equivalent to established preferred methods.

An abnormal result is not the end of screening

An abnormal stool test, CT colonography or flexible sigmoidoscopy result requires a follow-up colonoscopy to complete the screening process. The ACS says that follow-up should preferably occur within six months. Repeating a positive stool or blood test is not an appropriate substitute for diagnostic follow-up.

Cost questions are worth resolving before choosing a test. Federal guidance says that for many non-grandfathered private health plans, follow-up colonoscopy after a positive stool-based or direct-visualization screening test is part of preventive screening and must be covered without cost-sharing for people in the USPSTF-recommended population. Individual circumstances still vary. Medicare recognizes several colorectal screening services, including colonoscopy, CT colonography, flexible sigmoidoscopy, fecal occult blood testing and qualifying noninvasive biomarker tests.

How to choose an option

Start with three practical questions: Which test can you complete now? Will you repeat it on schedule? If it is abnormal, can you complete colonoscopy promptly? A test with a convenient collection method but poor follow-through is not a complete screening strategy.

Ask whether your personal or family history places you above average risk.
Compare the preparation, frequency, sedation and transportation requirements.
Confirm what your health plan covers, including follow-up colonoscopy.
Choose a reminder system for recurring stool tests or future structural exams.
Report symptoms rather than waiting for the next scheduled screening test.

No screening result guarantees that cancer is absent; false-negative and false-positive results can occur. The practical goal is therefore not to find a flawless test. It is to choose an evidence-supported pathway, complete it at the right interval and follow through when a result requires further evaluation.

Frequently asked questions

Is colonoscopy always the best screening test?

Not for everyone. Colonoscopy examines the entire colon and permits polyp removal, but an at-home test may be easier for some people to complete. The best strategy is one appropriate for the person’s risk level that can be completed and repeated reliably.

Can I repeat a stool test if the first result is positive?

No. A positive stool-based screening result calls for follow-up colonoscopy. Repeating the stool test can delay the diagnostic evaluation needed to understand the original result.

Does a negative stool test rule out colorectal cancer?

No. Screening tests can produce false-negative results. A negative result means the recommended screening interval continues; it does not mean symptoms should be ignored.

Do people over age 75 still need screening?

Sometimes. From ages 76 through 85, the decision is individualized according to health, life expectancy, prior screening and preferences. The ACS discourages screening after age 85.